232 related articles for article (PubMed ID: 20014922)
1. Discovery of prostate cancer biomarkers by microarray gene expression profiling.
Sørensen KD; Ørntoft TF
Expert Rev Mol Diagn; 2010 Jan; 10(1):49-64. PubMed ID: 20014922
[TBL] [Abstract][Full Text] [Related]
2. Cancer gene profiling in prostate cancer.
Foye A; Febbo PG
Methods Mol Biol; 2010; 576():293-326. PubMed ID: 19882268
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer and the genomic revolution: Advances using microarray analyses.
Calvo A; Gonzalez-Moreno O; Yoon CY; Huh JI; Desai K; Nguyen QT; Green JE
Mutat Res; 2005 Aug; 576(1-2):66-79. PubMed ID: 15950992
[TBL] [Abstract][Full Text] [Related]
4. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
Jiang Z; Woda BA; Wu CL; Yang XJ
Am J Clin Pathol; 2004 Aug; 122(2):275-89. PubMed ID: 15323145
[TBL] [Abstract][Full Text] [Related]
5. The role of tissue microarrays in prostate cancer biomarker discovery.
Datta MW; True LD; Nelson PS; Amin MB
Adv Anat Pathol; 2007 Nov; 14(6):408-18. PubMed ID: 18049130
[TBL] [Abstract][Full Text] [Related]
6. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
7. Cross-platform method for identifying candidate network biomarkers for prostate cancer.
Jin G; Zhou X; Cui K; Zhang XS; Chen L; Wong ST
IET Syst Biol; 2009 Nov; 3(6):505-12. PubMed ID: 19947776
[TBL] [Abstract][Full Text] [Related]
8. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.
Malinowski DP
Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.
Arencibia JM; Martín S; Pérez-Rodríguez FJ; Bonnin A
Int J Oncol; 2009 Feb; 34(2):457-63. PubMed ID: 19148481
[TBL] [Abstract][Full Text] [Related]
10. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens.
Li HR; Wang-Rodriguez J; Nair TM; Yeakley JM; Kwon YS; Bibikova M; Zheng C; Zhou L; Zhang K; Downs T; Fu XD; Fan JB
Cancer Res; 2006 Apr; 66(8):4079-88. PubMed ID: 16618727
[TBL] [Abstract][Full Text] [Related]
11. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
[TBL] [Abstract][Full Text] [Related]
12. Widespread deregulation of microRNA expression in human prostate cancer.
Ozen M; Creighton CJ; Ozdemir M; Ittmann M
Oncogene; 2008 Mar; 27(12):1788-93. PubMed ID: 17891175
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of non-small-cell lung cancer.
Lacroix L; Commo F; Soria JC
Expert Rev Mol Diagn; 2008 Mar; 8(2):167-78. PubMed ID: 18366303
[TBL] [Abstract][Full Text] [Related]
14. Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis.
Schlomm T; Luebke AM; Sültmann H; Hellwinkel OJ; Sauer U; Poustka A; David KA; Chun FK; Haese A; Graefen M; Erbersdobler A; Huland H
Int J Oncol; 2005 Sep; 27(3):713-20. PubMed ID: 16077921
[TBL] [Abstract][Full Text] [Related]
15. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
16. Identification of prognostic biomarkers for prostate cancer.
Kosari F; Munz JM; Savci-Heijink CD; Spiro C; Klee EW; Kube DM; Tillmans L; Slezak J; Karnes RJ; Cheville JC; Vasmatzis G
Clin Cancer Res; 2008 Mar; 14(6):1734-43. PubMed ID: 18347174
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A
J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095
[TBL] [Abstract][Full Text] [Related]
18. Genes differentially expressed in prostate cancer.
Eder IE; Bektic J; Haag P; Bartsch G; Klocker H
BJU Int; 2004 May; 93(8):1151-5. PubMed ID: 15142130
[TBL] [Abstract][Full Text] [Related]
19. Gene-expression profiling in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Cannistra SA
Nat Clin Pract Oncol; 2008 Oct; 5(10):577-87. PubMed ID: 18648354
[TBL] [Abstract][Full Text] [Related]
20. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer.
Welsh JB; Sapinoso LM; Su AI; Kern SG; Wang-Rodriguez J; Moskaluk CA; Frierson HF; Hampton GM
Cancer Res; 2001 Aug; 61(16):5974-8. PubMed ID: 11507037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
